Navigation Links
Medivation Announces Senior Management Promotions
Date:3/25/2008

SAN FRANCISCO, March 25 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the promotions of Michele D. Bronson, Ph.D., to vice president, regulatory and quality, Mohammad Hirmand, M.D., to vice president, clinical development, and Joyce Mordenti, Ph.D., to vice president, translational medicine.

"As we enter Phase 3 development for our lead product candidate, we are strengthening the team to lead and advance our clinical programs," said Lynn Seely, M.D., chief medical officer of Medivation. "Drs. Bronson, Hirmand and Mordenti's knowledge of the clinical trial and regulatory process will be invaluable as we move Dimebon forward in Alzheimer's and Huntington's diseases and complete our Phase 1-2 MDV3100 clinical trial in hormone-refractory prostate cancer. We look forward to their continued productivity and leadership."

Dr. Bronson joined Medivation in September 2006 as senior director, regulatory, quality and project management. She led the Company's end-of-Phase 2 meeting with the U.S. Food and Drug Administration for Dimebon(TM). Based on those discussions, Medivation plans to begin a pivotal confirmatory Phase 3 trial of Dimebon in mild-to-moderate Alzheimer's disease in the second quarter of 2008. Prior to joining Medivation, Dr. Bronson held positions of increasing responsibility in regulatory affairs at Chiron Corporation, including director in the oncology development organization, where she was responsible for approved products and developmental therapeutics. She joined Chiron Corporation from SEQUUS Pharmaceuticals where she was responsible for the development and accelerated approval of DOXIL for the treatment of ovarian cancer. Dr. Bronson began her career in drug development at Cato Researc
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
2. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Vital Imaging ™ has ... California, San Diego for a joint study which aims ... (Magnetic Resonance Imaging) with that of a supine Dynawell ... pursuit of improved healthcare by combining cutting edge technology ... extremely valuable tool for evaluating pathological changes in the ...
(Date:5/21/2013)... SoundConnect is pleased to announce the release ... in Canada. Lync is the next generation of ... and organizations to collaborate and communicate much more easily ... the United States. With the progressive rollout of Lync ... Canada, SoundConnect now offers a complete Microsoft Lync solution ...
(Date:5/21/2013)... May 21, 2013 The Formulate Fusion ... solution for sales and marketing teams looking for a fully-functional ... the kit as “everything you’ll need to put together a ... Kit comes with a number of displays and accessories that ... 20 feet by 20 feet in size. These components vary ...
(Date:5/20/2013)... May 20, 2013 , ... Research Service (ARS) in treatment of mastitis ... , Trials to begin in the second half ... technology company Phosphagenics Limited (ASX: POH, OTCQX: ... (USDA) Agricultural Research Service (ARS) to develop and trial ...
Breaking Biology Technology:Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3SoundConnect Announces Microsoft Lync Release in Canada 2SoundConnect Announces Microsoft Lync Release in Canada 3GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2Phosphagenics Signs Research Agreement with the Agricultural Research Service 2
... Elekta, a global leader in radiation,oncology and ... at the 49th Annual Meeting of The American ... reduce,treatment times and increase efficiency. The meeting will ... Los Angeles Convention Center (Los Angeles,California, USA). Elekta ...
... N.J., Oct. 18 NPS,Pharmaceuticals, Inc. (Nasdaq: NPSP ... cash tender offer for any and all of its ... at midnight, New,York City time, on October 17, 2007. ... offer, $171.2 million principal,amount of the notes, representing approximately ...
... Glycominds Ltd., a,biodiagnostics company specializing in glycan biomarkers ... cancer, announced today the,appointment of Dr. Chen Even ... Chen, a board member since 2004, contributes more ... "We are very pleased to elevate Dr. Even ...
Cached Biology Technology:Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007 2Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007 3Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007 4NPS Pharmaceuticals Announces Results of Tender Offer 2NPS Pharmaceuticals Announces Results of Tender Offer 3Glycominds Appoints Board of Directors Chairman 2Glycominds Appoints Board of Directors Chairman 3
(Date:5/21/2013)... Chicago College of Medicine will study gender differences in how ... source -- and how changes in fat metabolism play a ... grant from the National Heart, Lung and Blood Institute. , ... energy. These changes may play a major role in the ... women, says E. Douglas Lewandowski, director of the UIC Center ...
(Date:5/21/2013)... Where? Copenhagen, Denmark: Bella Center Congress Centre ... , Why? An annual meeting focusing ... manufacturing and installation, drawing on leading experiences from all ... from a record of more than 900 abstracts received ... and oral presentations, more than 460 visual presentation, 55 ...
(Date:5/20/2013)... the antibiotic colistin are also commonly resistant to ... to a study in mBio , the ... Microbiology. Cross-resistance to colistin and host antimicrobials LL-37 ... bacterial attack, could mean that patients with life-threatening ... crippled immune response. Colistin is a last-line drug ...
Breaking Biology News(10 mins):Do men's and women's hearts burn fuel differently? 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... A new study from The Montreal Neurological Institute and Hospital ... to discover a molecular link between Parkinson,s disease and defects ... published in the prestigious journal Molecular Cell and ... , provides new insight into the mechanisms underlying Parkinson,s disease, ...
... the molecular process that can shut down a marauding, ... who suffer battlefield casualties, heart attacks, strokes, automobile accidents ... the January edition of Molecular Immunology. , The ... of a reaction first observed in the lab by ...
... Diseases (NIAID), part of the National Institutes of Health ... Tulane University for its ongoing efforts to treat and ... threatens hundreds of thousands of people annually in West ... The contract will include collaboration between Tulane; Scripps ...
Cached Biology News:Communication breakdown: what happens to nerve cells in Parkinson's disease 2Communication breakdown: what happens to nerve cells in Parkinson's disease 3Research could lead to way to halt deadly immune response 2Research could lead to way to halt deadly immune response 3Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever 2
Peptide-affinity Purified Polyclonal Antibody to MTR...
Purified anti-eIF-4E...
Purified anti-PXR...
Goat polyclonal to MLH3 ( Abpromise for all tested applications). entrezGeneID: 27030 SwissProtID: Q9UHC1...
Biology Products: